MCID: MLG002
MIFTS: 51

Malignant Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Malignant Peritoneal Mesothelioma

MalaCards integrated aliases for Malignant Peritoneal Mesothelioma:

Name: Malignant Peritoneal Mesothelioma 55
Diffuse Malignant Peritoneal Mesothelioma 55
Primary Malignant Peritoneal Mesothelioma 55
Malignant Mesothelioma of Peritoneum 69

Characteristics:

Orphanet epidemiological data:

55
malignant peritoneal mesothelioma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (France),1-9/100000 (Europe),1-9/1000000 (Italy); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Orphanet 55 ORPHA168811
UMLS via Orphanet 70 C0346109
ICD10 via Orphanet 33 C45.1

Summaries for Malignant Peritoneal Mesothelioma

MalaCards based summary : Malignant Peritoneal Mesothelioma, also known as diffuse malignant peritoneal mesothelioma, is related to peritoneal mesothelioma and ovarian cancer 1, and has symptoms including ascites, weight loss and abnormality of coagulation. An important gene associated with Malignant Peritoneal Mesothelioma is VIM (Vimentin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Cytoskeletal Signaling. The drugs Doxorubicin and Ranpirnase have been mentioned in the context of this disorder. Affiliated tissues include t cells, colon and pancreas, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Related Diseases for Malignant Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Malignant Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 31.5 CDKN2A EGFR MUC1 NF2
2 ovarian cancer 1 30.0 EGFR MUC1
3 squamous cell carcinoma 29.6 CDKN2A EGFR MUC1
4 renal cell carcinoma, nonpapillary 29.5 EGFR MUC1 VIM
5 li-fraumeni syndrome 29.5 CDKN2A EGFR
6 adenocarcinoma 29.0 BIRC5 CDKN2A EGFR MUC1
7 peritonitis 11.0
8 papillary tumor of the pineal region 10.3 MUC1 VIM
9 parachordoma 10.3 MUC1 VIM
10 ossifying fibromyxoid tumor 10.3 MUC1 VIM
11 biphasic synovial sarcoma 10.3 MUC1 VIM
12 chordoid meningioma 10.3 MUC1 VIM
13 malignant mixed mullerian tumor 10.3 MUC1 VIM
14 nodular hidradenoma 10.3 MUC1 VIM
15 clear cell meningioma 10.3 MUC1 VIM
16 syringocystadenoma papilliferum 10.3 MUC1 VIM
17 eccrine porocarcinoma 10.3 MUC1 VIM
18 adenofibroma 10.3 MUC1 VIM
19 myxopapillary ependymoma 10.3 MUC1 VIM
20 monophasic synovial sarcoma 10.3 MUC1 VIM
21 syringoma 10.3 MUC1 VIM
22 hidradenoma 10.3 MUC1 VIM
23 perivascular epithelioid cell tumor 10.3 MUC1 VIM
24 reticulum cell sarcoma 10.3 MUC1 VIM
25 sertoli cell tumor 10.3 MUC1 VIM
26 mucinous cystadenocarcinoma 10.3 MUC1 VIM
27 chondroid chordoma 10.3 MUC1 VIM
28 spindle cell sarcoma 10.3 MUC1 VIM
29 mesenchymal chondrosarcoma 10.3 MUC1 VIM
30 extraskeletal ewing sarcoma 10.3 MUC1 VIM
31 perineurioma 10.3 MUC1 VIM
32 spiradenoma 10.3 MUC1 VIM
33 dermoid cyst 10.3 MUC1 VIM
34 dendritic cell tumor 10.3 MUC1 VIM
35 cerebral primitive neuroectodermal tumor 10.3 MUC1 VIM
36 hemangiopericytoma, malignant 10.3 MUC1 VIM
37 polymorphous low-grade adenocarcinoma 10.3 MUC1 VIM
38 papillary adenocarcinoma 10.3 MUC1 VIM
39 ameloblastic carcinoma 10.3 CDKN2A VIM
40 pericardial mesothelioma 10.3 MUC1 VIM
41 osteofibrous dysplasia 10.3 MUC1 VIM
42 malignant fibroxanthoma 10.3 MUC1 VIM
43 fasciitis 10.3 MUC1 VIM
44 optic nerve glioma 10.3 MUC1 VIM
45 breast scirrhous carcinoma 10.3 EGFR MUC1
46 epithelioid sarcoma 10.3 MUC1 VIM
47 endocervical adenocarcinoma 10.3 CDKN2A VIM
48 spindle cell carcinoma 10.2 MUC1 VIM
49 mucinous bronchioloalveolar adenocarcinoma 10.2 CDKN2A MUC1
50 rhabdoid cancer 10.2 MUC1 VIM

Graphical network of the top 20 diseases related to Malignant Peritoneal Mesothelioma:



Diseases related to Malignant Peritoneal Mesothelioma

Symptoms & Phenotypes for Malignant Peritoneal Mesothelioma

Human phenotypes related to Malignant Peritoneal Mesothelioma:

55 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 55 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
3 abnormality of coagulation 55 31 occasional (7.5%) Occasional (29-5%) HP:0001928
4 abdominal pain 55 31 hallmark (90%) Very frequent (99-80%) HP:0002027
5 dyspnea 55 31 occasional (7.5%) Occasional (29-5%) HP:0002094
6 peritonitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0002586
7 ileus 55 31 occasional (7.5%) Occasional (29-5%) HP:0002595
8 neoplasm 55 31 hallmark (90%) Very frequent (99-80%) HP:0002664
9 abdominal distention 55 31 hallmark (90%) Very frequent (99-80%) HP:0003270
10 edema of the lower limbs 55 31 occasional (7.5%) Occasional (29-5%) HP:0010741

UMLS symptoms related to Malignant Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MUC1 NF2 VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.8 EGFR MUC1 VIM

MGI Mouse Phenotypes related to Malignant Peritoneal Mesothelioma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.35 BIRC5 CDKN2A EGFR NF2 VIM
2 respiratory system MP:0005388 8.92 CDKN2A EGFR NF2 VIM

Drugs & Therapeutics for Malignant Peritoneal Mesothelioma

Drugs for Malignant Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2 Ranpirnase Investigational Phase 3 196488-72-9
3
Doxil Approved June 1999 Phase 3,Phase 2 31703
4 Topoisomerase Inhibitors Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2
6 Antibiotics, Antitubercular Phase 3,Phase 2
7
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Gemcitabine Approved Phase 2 95058-81-4 60750
9
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
10
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
11
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
12
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
13
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
14
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
15
Promethazine Approved, Investigational Phase 2 60-87-7 4927
16
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
17
Pancrelipase Approved, Investigational Phase 2 53608-75-6
18
Fluorouracil Approved Phase 2 51-21-8 3385
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
20
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
21
Pembrolizumab Approved Phase 2 1374853-91-4
22
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
23
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
24
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
25
Bevacizumab Approved, Investigational Phase 2 216974-75-3
26
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
28
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
29
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
30 interferons Phase 2,Phase 1
31 Alkylating Agents Phase 2,Phase 1
32 Mitomycins Phase 2
33 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 2,Phase 1
35 Anti-Infective Agents Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2,Phase 1
38 Antimetabolites Phase 2
39 Interferon-gamma Phase 2
40 Antimetabolites, Antineoplastic Phase 2
41 Antibodies Phase 2,Phase 1
42 Antiviral Agents Phase 2,Phase 1
43 pancreatin Phase 2
44 Ranitidine bismuth citrate Phase 2
45
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
46 Folic Acid Antagonists Phase 2,Phase 1
47 Albumin-Bound Paclitaxel Phase 2,Phase 1
48 Cortisol succinate Phase 2
49 Vitamin B Complex Phase 2,Phase 1
50 Peripheral Nervous System Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 31)

# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
5 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
8 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
9 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
10 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
11 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
12 Pembrolizumab in Treating Patients With Malignant Mesothelioma Recruiting NCT02399371 Phase 2
13 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
14 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Active, not recruiting NCT01160458 Phase 2 IMC-A12
15 Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
16 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
17 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
18 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
19 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
20 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Recruiting NCT03436732 Phase 1 LMB-100;SEL-110
21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
24 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
25 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
26 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
27 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
28 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
29 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
30 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
31 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Malignant Peritoneal Mesothelioma

Genetic Tests for Malignant Peritoneal Mesothelioma

Anatomical Context for Malignant Peritoneal Mesothelioma

MalaCards organs/tissues related to Malignant Peritoneal Mesothelioma:

38
T Cells, Colon, Pancreas, Lung, Lymph Node, Testis, Liver

Publications for Malignant Peritoneal Mesothelioma

Articles related to Malignant Peritoneal Mesothelioma:

(show top 50) (show all 278)
# Title Authors Year
1
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
2
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
3
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
4
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
5
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
6
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
7
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
8
Epidemiology of malignant peritoneal mesothelioma: A population-based study. ( 29080447 )
2017
9
Erratum: A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29267565 )
2017
10
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
11
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
12
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
13
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
14
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
15
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% ofA Malignant Peritoneal Mesotheliomas. ( 28034829 )
2017
16
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
17
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
18
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
19
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
20
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
21
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
22
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. ( 27813512 )
2016
23
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
24
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
25
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
26
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016
27
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
28
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016
29
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization-array. ( 27184482 )
2016
30
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. ( 27902597 )
2016
31
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. ( 27472649 )
2016
32
A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. ( 27438989 )
2016
33
Diagnosis and management of patients with malignant peritoneal mesothelioma. ( 26941986 )
2016
34
Malignant peritoneal mesothelioma in a patient with intestinal fistula, incisional hernia and abdominal infection: A case report. ( 26998119 )
2016
35
Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy. ( 27858561 )
2016
36
Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. ( 27281118 )
2016
37
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma. ( 27858557 )
2016
38
Renal cell carcinoma and malignant peritoneal mesothelioma after occupational asbestos exposure: case report. ( 27240221 )
2016
39
Malignant peritoneal mesothelioma and Crohn disease. ( 27484913 )
2016
40
Preventing recurrence of diffuse malignant peritoneal mesothelioma. ( 27486718 )
2016
41
CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. ( 26645426 )
2016
42
Computed Tomographic Features of Malignant Peritoneal Mesothelioma. ( 26976999 )
2016
43
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis. ( 26661955 )
2016
44
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma. ( 27428868 )
2016
45
The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). ( 26572754 )
2015
46
Establishment and mutation analysis of a novel malignant peritoneal mesothelioma cell line, TU-MM-1, using whole genome sequencing. ( 26070481 )
2015
47
Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. ( 26214083 )
2015
48
Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. ( 26227745 )
2015
49
Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment. ( 26545374 )
2015
50
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase III+, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray. ( 25777091 )
2015

Variations for Malignant Peritoneal Mesothelioma

Expression for Malignant Peritoneal Mesothelioma

Search GEO for disease gene expression data for Malignant Peritoneal Mesothelioma.

Pathways for Malignant Peritoneal Mesothelioma

GO Terms for Malignant Peritoneal Mesothelioma

Biological processes related to Malignant Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein sumoylation GO:0016925 9.16 BIRC5 CDKN2A
2 regulation of protein stability GO:0031647 8.96 CDKN2A NF2
3 negative regulation of cell-matrix adhesion GO:0001953 8.62 CDKN2A NF2

Sources for Malignant Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....